论文部分内容阅读
目的观察参麦注射液联合黄芪注射液辅治小儿病毒性心肌炎的临床疗效。方法将75例病毒性心肌炎患儿随机分为治疗组37例和对照组38例。对照组采用西医常规疗法,治疗组在常规治疗的基础上加用黄芪、参麦注射液。治疗4周后比较2组疗效。结果治疗组患者临床症状(胸闷、心悸、气短、乏力)改善总有效率高于对照组,差异有统计学意义(P<0.05);治疗组心电图改善总有效率为62.2%高于对照组的42.1%,差异有统计学意义(P<0.05)。2组治疗后红细胞沉降率(ESR)、肌酸激酶同工酶(CK-MB)、天冬氨酸氨基转移酶(AST)水平均降低,差异均有统计学意义(P<0.05或P<0.01)。治疗组治疗后CK-MB及AST水平均低于对照组,差异均有统计学意义(P<0.05)。结论参麦注射液联合黄芪注射液辅治小儿病毒性心肌炎,疗效显著,值得推广应用。
Objective To observe the clinical efficacy of Shenmai injection combined with astragalus injection in the treatment of viral myocarditis in children. Methods A total of 75 children with viral myocarditis were randomly divided into treatment group (37 cases) and control group (38 cases). The control group was treated with conventional western medicine. The treatment group was given astragalus and shenmai injection on the basis of routine treatment. After 4 weeks of treatment, the two groups were compared. Results The total effective rate of clinical symptoms (chest tightness, palpitations, shortness of breath, and fatigue) in the treatment group was significantly higher than that in the control group (P <0.05). The total effective rate in the treatment group was 62.2% 42.1%, the difference was statistically significant (P <0.05). The erythrocyte sedimentation rate (ESR), creatine kinase (CK-MB) and aspartate aminotransferase (AST) in the two groups were decreased after treatment, the differences were statistically significant (P <0.05 or P < 0.01). After treatment, the levels of CK-MB and AST in the treatment group were lower than those in the control group, with significant differences (P <0.05). Conclusion Shenmai injection combined with Astragalus injection in children with viral myocarditis, significant effect, it is worth promoting.